Radiology · 1993 · 94 citations · 0 references
MedicineNuclear MedicineRadiologyDiagnostic ImagingDiagnostic RadiologyEndocrine OncologyAdrenal ImagingEndocrine Tumor DiagnosisPheochromocytoma ImagingPositron Emission TomographyTumor DetectionTumor Imaging18F-fluorodeoxyglucose ImagingFluorine-18 Fluorodeoxyglucose Positron Emission TomographyIodine-123 Metaiodobenzylguanidine ScintigraphyMetaiodobenzylguanidine ImagingPheochromocytoma DetectionPheochromocytoma DiagnosisPositron Emission Tomography DetectionPositron Emission Tomography Localization
Many imaging methods can be used to detect pheochromocytoma, but some tumors are not detected with conventional modalities. To explore the possible usefulness of positron emission tomography (PET) after administration of 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) to localize pheochromocytoma in patients with false-negative scintigrams obtained after administration of metaiodobenzylguanidine (MIBG), FDG was administered and PET was performed in two adult patients with pheochromocytomas that had never been localized despite administration of MIBG. In both patients, images were obtained dynamically for 50 minutes; then a limited truncal sequence was performed. PET enabled correct localization of the tumors. In patient 1, a tumor that had not been detected for 21 years was localized in the middle mediastinum; in patient 2, a pheochromocytoma was detected in the right adrenal gland. PET performed after administration of FDG may be useful for localization of pheochromocytomas that do not accumulate MIBG.